Tesamorelin vs CJC-1295: GHRH Analog Comparison

Both tesamorelin and CJC-1295 are synthetic analogs of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that tells the pituitary to release growth hormone. However, they were engineered with different strategies to extend their short native half-life, leading to very different dosing regimens and use cases. This guide explains how they work, how they differ, and what the clinical evidence shows.

What is GHRH and why the need for analogs?

Native GHRH(1-44) is a 44-amino-acid peptide secreted by neurons in the hypothalamus. It enters the bloodstream, travels to the pituitary, binds GHRH receptors on somatotroph cells, and triggers growth hormone secretion. However, native GHRH has a major limitation: it is rapidly degraded by the serum enzyme dipeptidyl peptidase IV (DPP-IV), which cleaves the first two amino acids and inactivates the peptide. In human plasma, native GHRH's half-life is only 3–5 minutes.

To be useful therapeutically or in research, GHRH must be chemically modified to resist this rapid degradation.

Tesamorelin: DPP-IV resistance via N-terminal modification

Tesamorelin is a synthetic GHRH(1-44) analog with a trans-3-hexenoic acid group covalently attached to its N-terminus. This bulky modification is steric — it physically blocks DPP-IV from cleaving the first two amino acids, effectively rendering the peptide resistant to the enzyme.

Key properties:

• Half-life: 26–38 minutes (in human plasma).
• Dosing: Daily injection (once per day).
• GH release profile: Acute, short-lived spike with each injection.
• FDA approval: Yes. Approved in 2010 (brand name Egrifta) specifically for HIV-associated lipodystrophy (excess visceral fat, wasted limbs).
• Clinical evidence: Large, randomized controlled trials. A pooled analysis of two phase-3 trials (Falutz et al., J Clin Endocrinol Metab, 2010) randomized 806 ART-treated participants and reported a 15.4% treatment effect on visceral adipose tissue versus placebo at 26 weeks.

CJC-1295: Albumin-binding via DAC technology

CJC-1295 is a GHRH(1-29) analog (shorter than native GHRH, omitting the C-terminal 15 amino acids) engineered with Drug Affinity Complex (DAC) technology. The peptide is covalently conjugated to a small polymer that binds tightly to serum albumin, the most abundant blood protein. This albumin-binding acts as a "depot" — the peptide remains sequestered in the albumin complex and is released slowly over time.

Key properties:

• Half-life: Approximately 6–8 days (dramatically extended due to albumin binding).
• Dosing: Once per week or less frequently, depending on the protocol.
• GH release profile: Sustained, cumulative elevation over days; less pulsatile than tesamorelin.
• FDA approval: No. CJC-1295 has not been approved by the FDA for any therapeutic indication; it remains a research compound.
• Clinical evidence: Limited. Most data derive from small studies or proprietary company research; no large-scale randomized trials in peer-reviewed journals comparable to tesamorelin's Egrifta trials.

Structural differences at a glance

Which is better for research?

There is no single "better" choice — the decision depends on the research aim:

• Tesamorelin: Better if you need sharp, predictable GH pulses (mimicking the body's natural pulsatile secretion) or if you want the reassurance of clinical-grade evidence and FDA approval.
• CJC-1295: Better if you want sustained elevation of GH over days with less frequent dosing, and if your research hypothesis benefits from a tonic (baseline-elevated) rather than pulsatile GH profile.

Many research protocols use both peptides together — the idea being that CJC-1295 maintains a steady baseline of GH, while ipamorelin or another GHS (ghrelin secretagogue) adds acute pulses on top. This combination mimics the body's natural dual control of GH: tonic (GHRH) + pulsatile (ghrelin).

Clinical context: tesamorelin's real-world approval

Tesamorelin stands out as the only synthetic GHRH analog with FDA approval and documented clinical benefit. Egrifta was approved in 2010 specifically for the treatment of HIV-associated lipodystrophy — a condition in which antiretroviral therapy causes preferential fat loss in the limbs and face, with paradoxical fat accumulation in the abdomen and chest. The pooled phase-3 analysis published in the Journal of Clinical Endocrinology & Metabolism showed that 26 weeks of daily tesamorelin produced a 15.4% treatment effect on visceral adipose tissue relative to placebo, and that the reduction was maintained through 52 weeks.

This approval history is important because it means tesamorelin has undergone the rigorous safety and efficacy vetting that the FDA requires for human use, whereas CJC-1295 and other research peptides have not.

Growth hormone peptides for research

Universe Peptide supplies both GHRH analogs and growth hormone secretagogues with third-party Certificates of Analysis:

• Browse all growth hormone research peptides
• GHRH Receptor & the GH-IGF-1 Axis
• CJC-1295 & Ipamorelin: Secretagogue Research

Shop growth hormone peptides →

Sources & further reading

• Falutz J, et al. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data. J Clin Endocrinol Metab. 2010;95(9):4291–4304. PubMed 20554713
• Falutz J, et al. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. N Engl J Med. 2007;357:2359–2370. NEJMoa072375
• Stanley TL, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014. PubMed 25038357
• Falutz J, et al. Long-Term Safety and Effects of Tesamorelin, a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Abdominal Fat Accumulation. PubMed 18690162
• National Institutes of Health — Tesamorelin. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf NBK548730